In a world where many companies are venturing into cancer research, Seattle Genetics has been able to stand out. This company’s success is attributed to its vision and its CEO, Dr. Clay Siegall. For years, Dr.Siegall has strived to improve the lives of cancer patients through the development of cancer therapies. He has served as the CEO this company for the last 20 years.
Dr. Siegall achievements in the field of bio-medicine
Dr.Siegall has worked for Bristol-Myers Research Institute as a high-ranking researcher. He then moved to National Cancer Institute as the head of cancer research department. Dr. Siegall has always been committed to conducting in-depth research and implementation of research developments. His primary objective is to alleviate pain and suffering from cancer patients. It is his love and dedication to research that has enabled his company to develop some of the world’s famous drug conjugates. Under his management, Seattle Genetics was able to develop ADCs, such as ADCETRIS. This medication was approved for use by the FDA in 2011, following a series of clinical trials. Since its approval, the use ADCETRIS has expanded to more than 60 nations around the world.
About Dr. Clay Siegall
Dr. Clay Siegall works at Seattle Genetics, a unique biotechnology giant that pioneers in the development, commercialization, and distribution of cancer therapies. He is a zoologist by training with a vested interest in biomedical sciences. Dr. Siegall is the driving force behind the development of antibody- drug conjugates. As the head of the biotechnological heavyweight dubbed Seattle Genetics, Dr. Clay has played a huge role in capital-raising endeavors. Since the company was formed, Dr. Siegall has been able to raise over $1.2 billion and facilitated the firm’s initial public offering.
Dr. Siegall’s efforts in the scientific community have been honored severally. He scooped the Alumnus of the Year Accolade issued by the University of Maryland and the respected Young Entrepreneur of the Year. Dr. Siegall is the head of various boards that range from the Board of Ultragenyx Pharmaceutical to Alder Biopharmaceuticals. When not busy in office handling day-to-day tasks of his biotechnology company, Dr. Clay would be busy writing scientific articles and book chapters.